CollPlant Biotechnologies announced on April 15, 2025, that its Collink.3D® rhCollagen-based BioInks and technologies offer a solution aligned with the United States Food and Drug Administration's (FDA) plan to reduce animal testing. The FDA's initiative, announced on April 10, 2025, aims to replace animal testing with more effective, human-relevant methods for drug development.
CollPlant's Collink.3D® portfolio of BioInk products can be utilized for the biofabrication of tissue-on-a-chip or organ-on-a-chip systems, which serve as alternatives to traditional animal testing. These systems are designed to expedite the gap between benchtop studies and clinical trials, offering more economical and faster development pathways.
The company also highlighted its Computational Modeling and Simulation (CM&S) methodologies, used in developing its regenerative breast implant, as tools that reduce the need for animal studies. This strategic alignment positions CollPlant's technology as a timely solution for improving drug safety, accelerating evaluation processes, and reducing research and development costs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.